While clues have existed that endosomal trafficking is associated with Alzheimer's disease (AD), whether it plays a central role in the disease and if so how has remained unknown. Here we rely on recent genetic and cellular findings to construct a model proposing that traffic jams in the early endosome can act as an upstream pathogenic hub in AD. We also rely on an independent series of findings to suggest how the traffic jams can act as a unified mediator of downstream pathophysiology. The model predicts, therefore, that interventions designed to unjam the endosome carry high therapeutic promise.
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Four Classes of Genes Linked to AD
The turn of the century represents a convenient timestamp around which the genetic investigation into AD can be organized. Available genetic tools at the end of the 20th century were best suited to isolate Mendelian-inherited mutations, and when applied to the rare autosomaldominant forms of AD identified mutations in genes encoding the amyloid precursor protein (APP) and the presenilins, presenilin1 (PSEN1) and presenilin 2 (PSEN2) [1] . During the early part of the 21st century, new tools, large samples, and computational prowess allowed the focus to shift to the more common late-onset sporadic form of AD, which accounts for >95% of all cases. These genetic studies have revealed approximately two dozen genes linked to lateonset AD [2] [3] [4] . Remarkably, the genes cohere into three general biological classes: cholesterol metabolism, immune response, and endosomal trafficking. Thus, together with the class of APP processing genes associated with autosomal-dominant disease, there are now four main gene classes that are linked to AD.
In this Opinion, we rely on recent insight into the function of these genes, together with their intraneuronal effects to construct a testable pathogenic model of disease that is centered on endosomal traffic jams (Figure 1) . The model proposes that endosomal traffic jams represent a pathogenic hub onto which nearly all AD genes can directly or indirectly converge, and suggests that this hub can act as a final common pathway through which many downstream pathophysiological effects can be mediated. If validated, this model predicts that immunotherapies directed against extracellular amyloid plaques might fail even if administered early, and suggests alternative cell biological targets for therapeutic interventions.
Endosomal Traffic Jams in AD
The first indication that endosomal traffic jams can occur in AD came from a careful microscopic analysis of postmortem brains showing that abnormal enlargement of the early endosome Trends While defects in intracellular trafficking have long been suspected in AD, recent genetic findings localize the defect, specifically, to trafficking in and out of endosomes.
Endosomal traffic jams can be caused directly, for example, by endosomal genetic defects, or secondarily, by any defect that increases intracellular amyloid.
Endosomal traffic jams can mediate downstream toxicity, by reducing glutamate receptor recycling, leading to synaptic dysfunction, and potentially by increasing transsynaptic spread by altering the content of exosomes.
Endosomal traffic jams can be considered a validated cell biological target for AD drug discovery.
Because endosomal traffic jams occur early in the disease, and might occur in an amyloid-independent manner, we argue that drugs that unjam the endosome carry high therapeutic promise.
